PROTAC drug vepdegestrant approved for breast cancer
FDA has approved the first PROTAC drug vepdegestrant (Veppanu) for the treatment of breast cancer. Learn how proteolysis-targeting chimera reduces the risk of progression by 43% and opens a new era in oncology.
